120 related articles for article (PubMed ID: 20156945)
1. Elevated serum concentrations of triggering receptor expressed on myeloid cells-1 in diffuse cutaneous systemic sclerosis: association with severity of pulmonary fibrosis.
Tomita H; Ogawa F; Hara T; Yanaba K; Iwata Y; Muroi E; Yoshizaki A; Komura K; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
J Rheumatol; 2010 Apr; 37(4):787-91. PubMed ID: 20156945
[TBL] [Abstract][Full Text] [Related]
2. Increased serum pentraxin 3 in patients with systemic sclerosis.
Iwata Y; Yoshizaki A; Ogawa F; Komura K; Hara T; Muroi E; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Takehara K; Sato S
J Rheumatol; 2009 May; 36(5):976-83. PubMed ID: 19273457
[TBL] [Abstract][Full Text] [Related]
3. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis.
Sato S; Fujimoto M; Hasegawa M; Komura K; Yanaba K; Hayakawa I; Matsushita T; Takehara K
Rheumatology (Oxford); 2004 Oct; 43(10):1261-6. PubMed ID: 15266059
[TBL] [Abstract][Full Text] [Related]
4. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis.
Kodera M; Hasegawa M; Komura K; Yanaba K; Takehara K; Sato S
Arthritis Rheum; 2005 Sep; 52(9):2889-96. PubMed ID: 16142750
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis.
Ogawa F; Shimizu K; Muroi E; Hara T; Hasegawa M; Takehara K; Sato S
Rheumatology (Oxford); 2006 Jul; 45(7):815-8. PubMed ID: 16449367
[TBL] [Abstract][Full Text] [Related]
6. Elevated serum concentrations of polymorphonuclear neutrophilic leukocyte elastase in systemic sclerosis: association with pulmonary fibrosis.
Hara T; Ogawa F; Yanaba K; Iwata Y; Muroi E; Komura K; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
J Rheumatol; 2009 Jan; 36(1):99-105. PubMed ID: 19208531
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum insulin-like growth factor (IGF-1) and IGF binding protein-3 levels in patients with systemic sclerosis: possible role in development of fibrosis.
Hamaguchi Y; Fujimoto M; Matsushita T; Hasegawa M; Takehara K; Sato S
J Rheumatol; 2008 Dec; 35(12):2363-71. PubMed ID: 19004037
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis.
Hasegawa M; Sato S; Fujimoto M; Ihn H; Kikuchi K; Takehara K
J Rheumatol; 1998 Feb; 25(2):308-13. PubMed ID: 9489824
[TBL] [Abstract][Full Text] [Related]
9. Serum concentrations of soluble P-selectin glycoprotein ligand-1 are increased in patients with systemic sclerosis: association with lower frequency of pulmonary fibrosis.
Yanaba K; Takehara K; Sato S
Ann Rheum Dis; 2004 May; 63(5):583-7. PubMed ID: 15082492
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of soluble CD31 in patients with systemic sclerosis (SSc): association with limited cutaneous SSc.
Sato S; Komura K; Hasegawa M; Fujimoto M; Takehara K
J Rheumatol; 2001 Nov; 28(11):2460-5. PubMed ID: 11708419
[TBL] [Abstract][Full Text] [Related]
11. Increased serum soluble CD40 levels in patients with systemic sclerosis.
Komura K; Fujimoto M; Matsushita T; Yanaba K; Kodera M; Kawasuji A; Hasegawa M; Takehara K; Sato S
J Rheumatol; 2007 Feb; 34(2):353-8. PubMed ID: 17295440
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of monocyte chemotactic protein-3/CCL7 are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis.
Yanaba K; Komura K; Kodera M; Matsushita T; Hasegawa M; Takehara K; Sato S
Ann Rheum Dis; 2006 Jan; 65(1):124-6. PubMed ID: 16344498
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
Asano Y; Ihn H; Yamane K; Yazawa N; Kubo M; Fujimoto M; Tamaki K
Arthritis Rheum; 2001 Jun; 44(6):1363-9. PubMed ID: 11407696
[TBL] [Abstract][Full Text] [Related]
14. Elevated circulating TWEAK levels in systemic sclerosis: association with lower frequency of pulmonary fibrosis.
Yanaba K; Yoshizaki A; Muroi E; Hara T; Ogawa F; Usui A; Hasegawa M; Fujimoto M; Takehara K; Sato S
J Rheumatol; 2009 Aug; 36(8):1657-62. PubMed ID: 19531747
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
Yamane K; Ihn H; Kubo M; Yazawa N; Kikuchi K; Soma Y; Tamaki K
J Rheumatol; 2000 Apr; 27(4):930-4. PubMed ID: 10782818
[TBL] [Abstract][Full Text] [Related]
16. Anti-p53 autoantibody in systemic sclerosis: association with limited cutaneous systemic sclerosis.
Hara T; Ogawa F; Muroi E; Komura K; Takenaka M; Hasegawa M; Fujimoto M; Sato S
J Rheumatol; 2008 Mar; 35(3):451-7. PubMed ID: 18203319
[TBL] [Abstract][Full Text] [Related]
17. Elevated circulating CD40L concentrations in patients with systemic sclerosis.
Komura K; Sato S; Hasegawa M; Fujimoto M; Takehara K
J Rheumatol; 2004 Mar; 31(3):514-9. PubMed ID: 14994397
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis.
Fujii H; Shimada Y; Hasegawa M; Takehara K; Sato S
J Dermatol Sci; 2004 Jun; 35(1):43-51. PubMed ID: 15194146
[TBL] [Abstract][Full Text] [Related]
19. Increased levels of soluble triggering receptor expressed on myeloid cells-1 in patients with acute pancreatitis.
Yasuda T; Takeyama Y; Ueda T; Shinzeki M; Sawa H; Takahiro N; Kamei K; Ku Y; Kuroda Y; Ohyanagi H
Crit Care Med; 2008 Jul; 36(7):2048-53. PubMed ID: 18552693
[TBL] [Abstract][Full Text] [Related]
20. Soluble triggering receptor expressed on myeloid cell-1 (sTREM-1): a new mediator involved in early ankylosing spondylitis.
Chen CH; Liao HT; Chen HA; Liang TH; Wang CT; Chou CT
J Rheumatol; 2008 Sep; 35(9):1846-8. PubMed ID: 18634145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
